Genmab A/S (NASDAQ:GMAB) Shares Purchased by Assetmark Inc.

Assetmark Inc. boosted its holdings in Genmab A/S (NASDAQ:GMAB) by 16.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 82,629 shares of the company’s stock after buying an additional 11,519 shares during the period. Assetmark Inc.’s holdings in Genmab A/S were worth $2,014,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Capital International Investors boosted its position in shares of Genmab A/S by 7.8% in the first quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock worth $130,805,000 after buying an additional 315,355 shares during the period. Renaissance Technologies LLC boosted its holdings in Genmab A/S by 7.6% in the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock worth $36,752,000 after acquiring an additional 103,859 shares during the period. DDD Partners LLC purchased a new position in Genmab A/S in the 2nd quarter worth approximately $8,860,000. Cubist Systematic Strategies LLC grew its position in Genmab A/S by 109.7% in the second quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock valued at $7,000,000 after acquiring an additional 145,689 shares in the last quarter. Finally, Ingalls & Snyder LLC raised its stake in shares of Genmab A/S by 29.3% during the second quarter. Ingalls & Snyder LLC now owns 229,700 shares of the company’s stock valued at $5,772,000 after purchasing an additional 52,117 shares during the period. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Price Performance

Shares of Genmab A/S stock opened at $21.66 on Thursday. Genmab A/S has a 1-year low of $21.59 and a 1-year high of $32.89. The business’s fifty day moving average price is $24.20 and its two-hundred day moving average price is $26.31. The company has a market capitalization of $14.33 billion, a P/E ratio of 21.03, a PEG ratio of 0.70 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). The company had revenue of $816.10 million for the quarter, compared to the consensus estimate of $838.20 million. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. During the same quarter last year, the firm posted $0.47 earnings per share. On average, research analysts expect that Genmab A/S will post 1.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Redburn Atlantic assumed coverage on Genmab A/S in a research note on Tuesday, October 8th. They issued a “buy” rating on the stock. Truist Financial reduced their target price on Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, September 9th. Morgan Stanley restated an “equal weight” rating and issued a $31.00 price target on shares of Genmab A/S in a research note on Wednesday, September 11th. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research note on Wednesday, October 16th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.20.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.